The toxicity of nonsteroidal anti-inflammatory drugs (NSAIDs) is one of the major limitations to their long-term use in the treatment of chronic inflammatory conditions. This review provides an overview of the preclinical efforts on the development of nanodelivery systems for NSAIDs with a focus on the effect of nanoformulation on the pharmacokinetics and pharmacodynamics of the delivered drugs. Preclinical and clinical studies have shown that nanomedicine products can reduce toxicity and enhance the efficacy of certain encapsulated therapeutics. In this context, significant effort has been devoted to the development of nanodelivery systems for NSAIDs as means in reducing their side effects. Indeed, the preclinical studies on NSAID nanoformulations have been shown to reduce the toxicity while enhancing the bioavailability of incorporated NSAIDs at equal doses compared to conventional NSAID formulations. Furthermore, compared to conventional formulations, a number of nanoformulations were able to sustain the release of the loaded NSAIDs, and improve the pharmacodynamics of the encapsulated drug in preclinical models of inflammatory diseases. These advantages have been demonstrated using various routes of administration including oral, parenteral, ocular, transdermal, and others for the nanoformulations. A review of the research results implies a great potential for the use of nanotechnology in improving the quality of life for patients taking NSAIDs for chronic conditions, through reducing drug side effects or frequency of administration. The approach may also enable the administration of higher doses of NSAID needed for off-label therapeutic indications for diseases like Alzheimer’s and Parkinson’s.

非甾体抗炎药（NSAIDs）的毒性是长期用于治疗慢性炎性疾病的主要限制之一。这篇综述概述了NSAIDs纳米递送系统开发的临床前工作，重点是纳米制剂对所递送药物的药代动力学和药效学的影响。临床前和临床研究表明，纳米药物产品可以降低毒性并增强某些封装疗法的功效。在这种情况下，已经做出了巨大的努力来开发用于NSAID的纳米递送系统，以减少其副作用。的确，与传统的NSAID制剂相比，NSAID纳米制剂的临床前研究已显示出在降低毒性的同时提高了掺入的NSAIDs在相同剂量下的生物利用度。此外，与常规制剂相比，许多纳米制剂能够在炎性疾病的临床前模型中维持负载的NSAID的释放，并改善包封的药物的药效学。这些优点已经使用各种给药途径证明，包括口服，肠胃外，眼，透皮和其他用于纳米制剂的给药途径。对研究结果的回顾表明，通过减少药物副作用或给药频率，使用纳米技术改善服用NSAIDs的慢性病患者的生活质量具有巨大潜力。